Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Altace ANDAs On Hold Till June; Colbalt Gets Exclusivity, Not “Parking” Ticket

Executive Summary

Lupin Pharmaceuticals and five other pharma companies will have to wait at least until June to market their versions of ramipril capsules (King's Altace), as FDA ruled that Cobalt Pharmaceuticals is entitled to the 180-day generic drug exclusivity it was granted in 2005

You may also be interested in...

Generic Exclusivity Debate Continues At FDA: What Counts As A Forfeit?

FDA is continuing its case-by-case review of the 180-day exclusivity status for ANDAs as they approach marketing - most recently for generics of Bayer's Precose (acarbose), King's Altace (ramipril) and Roche's Kytril (granisetron)

Generic ramipril not obvious to King

King is hoping to delay entry of generics versions of its ACE inhibitor Altace (ramipril) with a motion for hearing and rehearing en banc following a Federal Circuit decision, which invalidated King's '722 patent on the basis of obviousness. The Federal Circuit overturned an earlier decision that had upheld the validity of King's patent, instead ruling in favor of appellant Lupin. Teva, Actavis, Sandoz, Roxane and Dr. Reddy's each have a tentative approval for generic ramipril. King is hoping to spark growth of its top product, which has accounted for 32 percent of the firm's sales over the last 12 months, by launching a new tablet formulation and by gaining approval of a ramipril/hydrochlorothiazide combination (1"The Pink Sheet" Aug. 13, 2007, p. 12)...

Pharma's Reform Bounce: How Big a Bounce Will $80 Bil. Buy?

Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts